SMT202500454T1 - Anticorpi umani contro la glicoproteina del virus ebola - Google Patents
Anticorpi umani contro la glicoproteina del virus ebolaInfo
- Publication number
- SMT202500454T1 SMT202500454T1 SM20250454T SMT202500454T SMT202500454T1 SM T202500454 T1 SMT202500454 T1 SM T202500454T1 SM 20250454 T SM20250454 T SM 20250454T SM T202500454 T SMT202500454 T SM T202500454T SM T202500454 T1 SMT202500454 T1 SM T202500454T1
- Authority
- SM
- San Marino
- Prior art keywords
- human antibodies
- ebola virus
- virus glycoprotein
- glycoprotein
- ebola
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107581P | 2015-01-26 | 2015-01-26 | |
| US201562161356P | 2015-05-14 | 2015-05-14 | |
| US201562245703P | 2015-10-23 | 2015-10-23 | |
| EP16703030.3A EP3250591B1 (en) | 2015-01-26 | 2016-01-25 | Human antibodies to ebola virus glycoprotein |
| PCT/US2016/014720 WO2016123019A1 (en) | 2015-01-26 | 2016-01-25 | Human antibodies to ebola virus glycoprotein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202500454T1 true SMT202500454T1 (it) | 2026-01-12 |
Family
ID=55300806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20250454T SMT202500454T1 (it) | 2015-01-26 | 2016-01-25 | Anticorpi umani contro la glicoproteina del virus ebola |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9771414B2 (enExample) |
| EP (2) | EP4653051A3 (enExample) |
| JP (4) | JP6829199B2 (enExample) |
| KR (1) | KR102641731B1 (enExample) |
| CN (2) | CN107667115B (enExample) |
| AU (2) | AU2016211783B2 (enExample) |
| BR (1) | BR112017015845A2 (enExample) |
| CA (1) | CA2974899A1 (enExample) |
| CL (3) | CL2017001920A1 (enExample) |
| CO (1) | CO2017007619A2 (enExample) |
| DK (1) | DK3250591T3 (enExample) |
| EA (1) | EA038993B1 (enExample) |
| ES (1) | ES3054263T3 (enExample) |
| FI (1) | FI3250591T3 (enExample) |
| HR (1) | HRP20251642T1 (enExample) |
| IL (1) | IL253358B (enExample) |
| LT (1) | LT3250591T (enExample) |
| MA (1) | MA41421B1 (enExample) |
| MD (1) | MD3250591T2 (enExample) |
| MX (2) | MX392533B (enExample) |
| MY (4) | MY180045A (enExample) |
| PH (1) | PH12017501277B1 (enExample) |
| PL (1) | PL3250591T3 (enExample) |
| PT (1) | PT3250591T (enExample) |
| RS (1) | RS67563B1 (enExample) |
| SG (2) | SG10202007835QA (enExample) |
| SI (1) | SI3250591T1 (enExample) |
| SM (1) | SMT202500454T1 (enExample) |
| TW (1) | TWI710573B (enExample) |
| UY (1) | UY36538A (enExample) |
| WO (1) | WO2016123019A1 (enExample) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| ES2655051T3 (es) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AR102198A1 (es) | 2014-10-09 | 2017-02-08 | Regeneron Pharma | Proceso para reducir partículas subvisibles en una formulación farmacéutica |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| JP2019510481A (ja) | 2016-02-19 | 2019-04-18 | ウィスコンシン アルムニ リサーチ ファンデイション | ワクチン開発のための改善されたｂ型インフルエンザウイルス複製 |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| US20200148750A1 (en) | 2016-07-21 | 2020-05-14 | Emory University | Ebola Virus Antibodies and Binding Agents Derived Therefrom |
| AU2017312785B2 (en) | 2016-08-16 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| KR102759512B1 (ko) | 2016-10-25 | 2025-02-03 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피 데이터 분석을 위한 방법 및 시스템 |
| CN113512111B (zh) * | 2017-03-10 | 2023-08-15 | 北京天广实生物技术股份有限公司 | 抗埃博拉病毒单克隆抗体、其制备方法及用途 |
| KR20210084695A (ko) | 2017-07-06 | 2021-07-07 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| WO2019139648A2 (en) * | 2017-09-15 | 2019-07-18 | David Weiner | Dna antibody constructs for use against ebola virus |
| WO2019060062A1 (en) | 2017-09-19 | 2019-03-28 | Regeneron Pharmaceuticals Inc. | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| RU2686630C1 (ru) * | 2017-12-22 | 2019-04-29 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Штаммы гибридных клеток животных Mus. Musculus - продуценты моноклональных антител к белку GP вируса Эбола (subtype Zaire) и моноклональные антитела к белку GP вируса Эбола (subtype Zaire) |
| US20190194298A1 (en) | 2017-12-22 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| US11976109B2 (en) | 2018-01-02 | 2024-05-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| CA3085177A1 (en) | 2018-01-31 | 2019-08-08 | Regeneron Pharamaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| US12697386B2 (en) | 2018-01-31 | 2026-08-04 | The Wistar Institute Of Anatomy And Biology | Nucleic acid antibody constructs for use against Ebola virus |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| AU2019227531B2 (en) | 2018-02-28 | 2025-01-30 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| CN108373500A (zh) * | 2018-03-12 | 2018-08-07 | 中国科学院微生物研究所 | 一种热稳定性埃博拉治疗性抗体的制备及应用 |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US11054389B2 (en) | 2018-03-19 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| WO2019190931A1 (en) * | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Anti-pfrh5 antibodies and antigen-binding fragments thereof |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| TWI919355B (zh) | 2018-07-02 | 2026-03-21 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| US11939370B2 (en) * | 2018-07-12 | 2024-03-26 | Vanderbilt University | Pan-ebola virus neutralizing human antibodies and methods of use therefor |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| US11389523B2 (en) | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| WO2020047067A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| MX2021005048A (es) | 2018-10-31 | 2021-09-08 | Bioatla Inc | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. |
| CN111138531B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 特异结合于ebov的gp1亚基的单克隆抗体8f9及应用 |
| CN111138528B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 特异性结合于埃博拉病毒糖蛋白聚糖帽的单克隆抗体5a8 |
| CN111138527B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用 |
| CN111138526B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 一种抗埃博拉病毒糖蛋白gp2亚基的单克隆抗体2g1及应用 |
| JP2022517720A (ja) | 2019-01-16 | 2022-03-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ジスルフィド結合を特徴付けるための方法 |
| WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| EA202192422A1 (ru) | 2019-03-05 | 2021-12-09 | Ридженерон Фармасьютикалз, Инк. | Человеческий сывороточный альбумин в составах |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| JP7541534B2 (ja) | 2019-05-13 | 2024-08-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された競合的リガンド結合アッセイ |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| JP6761889B1 (ja) * | 2019-11-11 | 2020-09-30 | 株式会社Ｇｓｐエンタープライズ | 抗ヒトＣｒｉｐｔｏ−１抗体 |
| US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| GB201917480D0 (en) * | 2019-11-29 | 2020-01-15 | Univ Oxford Innovation Ltd | Antibodies |
| CA3165060C (en) | 2020-01-21 | 2023-06-20 | Yiming Zhao | Deglycosylation methods for electrophoresis of glycosylated proteins |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| MX2022008949A (es) * | 2020-01-24 | 2022-08-15 | Regeneron Pharma | Formulacion de anticuerpos estable. |
| HUE062777T2 (hu) | 2020-02-26 | 2023-12-28 | Vir Biotechnology Inc | SARS-CoV-2 elleni antitestek |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| MX2022014598A (es) | 2020-05-26 | 2023-03-31 | Regeneron Pharma | Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno. |
| US12605459B2 (en) * | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| KR20230058094A (ko) | 2020-08-31 | 2023-05-02 | 리제너론 파아마슈티컬스, 인크. | 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략 |
| WO2022074630A1 (en) * | 2020-10-09 | 2022-04-14 | Auxilla Pharmaceuticals And Research Llp | Liquid oral suspension of favipiravir |
| EP4251128A1 (en) | 2020-11-25 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| IL303675A (en) | 2020-12-17 | 2023-08-01 | Regeneron Pharma | Production of protein thermal microgels |
| WO2022150809A1 (en) * | 2021-01-05 | 2022-07-14 | Immunome, Inc. | Antibody cocktail against sars-cov-2 spike protein |
| MX2023008527A (es) | 2021-01-20 | 2023-07-28 | Regeneron Pharma | Metodos para mejorar el valor proteico en cultivo celular. |
| TW202246325A (zh) | 2021-03-03 | 2022-12-01 | 美商再生元醫藥公司 | 用於定量及修飾蛋白質黏度之系統及方法 |
| AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
| AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| EP4413364A2 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| EP4413359A1 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| WO2023076340A1 (en) | 2021-10-26 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| MX2024008361A (es) | 2022-01-14 | 2024-09-10 | Regeneron Pharma | Derivados de verrucarina a y conjugados anticuerpo-fármaco de los mismos. |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| US20240248097A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| EP4669963A2 (en) | 2023-02-22 | 2025-12-31 | Regeneron Pharmaceuticals, Inc. | SYSTEM FITNESS PARAMETERS AND COLUMN AGING |
| JP2026514305A (ja) | 2023-05-01 | 2026-05-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | フェノールまたはベンジルアルコールを使用した複数回投与抗体医薬品 |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| CN122138969A (zh) | 2023-10-18 | 2026-06-02 | 瑞泽恩制药公司 | 从过程中上游细胞培养物材料中快速纯化单克隆抗体 |
| AU2024373307A1 (en) | 2023-11-02 | 2026-05-14 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| TW202600593A (zh) | 2024-02-16 | 2026-01-01 | 美商再生元醫藥公司 | 製造濃縮配製包括蛋白質之藥品物質之方法，以及該方法製造之濃縮配製之藥品物質 |
| TW202602489A (zh) | 2024-03-15 | 2026-01-16 | 美商再生元醫藥公司 | 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐 |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
| CN120943942A (zh) * | 2024-09-12 | 2025-11-14 | 南京诺唯赞生物科技股份有限公司 | 特异性结合hpv的抗体 |
| WO2026060350A1 (en) | 2024-09-13 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods |
| WO2026076201A2 (en) | 2024-10-03 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools |
| WO2026080597A1 (en) | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
| WO2026112457A2 (en) | 2024-11-21 | 2026-05-28 | Regeneron Pharmaceuticals, Inc. | Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof |
| WO2026136650A1 (en) | 2024-12-20 | 2026-06-25 | Regeneron Pharmaceuticals, Inc. | Fixed seed train schedule for improved protein production |
| CN120623329B (zh) * | 2025-01-15 | 2026-04-10 | 中国人民解放军军事科学院军事医学研究院 | 抗埃博拉病毒vp40蛋白的纳米抗体3e07及在病毒检测中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7089600A (en) | 1999-08-30 | 2001-03-26 | U.S. Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| EP2262832A4 (en) | 2008-02-01 | 2011-03-09 | Ca Minister Health & Welfare | MONOCLONAL ANTIBODIES TO EBOLA AND MARBURG VIRUSES |
| WO2010048615A2 (en) | 2008-10-24 | 2010-04-29 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention | Human ebola virus species and compositions and methods thereof |
| DK2808393T3 (en) | 2009-06-02 | 2018-03-12 | Regeneron Pharma | Cells insufficient for fucosylation |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| EP2473525A4 (en) | 2009-09-02 | 2013-08-21 | Us Army | MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS |
| US9346875B2 (en) | 2013-06-03 | 2016-05-24 | Albert Einstein College Of Medicine, Inc. | Therapy for filovirus infection |
| US20170183396A1 (en) | 2014-02-19 | 2017-06-29 | Jody Berry | Ebola monoclonal antibodies |
| CN103864904B (zh) * | 2014-03-04 | 2016-01-20 | 中国人民解放军军事医学科学院生物工程研究所 | 基于埃博拉病毒包膜蛋白的抗原片段、截短体及应用 |
| WO2015200522A2 (en) | 2014-06-25 | 2015-12-30 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
| US10435461B2 (en) | 2014-08-20 | 2019-10-08 | Albert Einstein College Of Medicine | Therapy for filovirus infection |
| WO2016054598A2 (en) | 2014-10-03 | 2016-04-07 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| US10640549B2 (en) | 2014-10-17 | 2020-05-05 | University Of Virginia Patent Foundation | Recombinant antibodies that recognize the C-terminal domains of Ebola virus nucleoprotein |
| TWI710573B (zh) * | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
-
2016
- 2016-01-22 TW TW105101967A patent/TWI710573B/zh active
- 2016-01-24 MA MA41421A patent/MA41421B1/fr unknown
- 2016-01-25 EP EP25206939.8A patent/EP4653051A3/en active Pending
- 2016-01-25 CN CN201680018389.XA patent/CN107667115B/zh active Active
- 2016-01-25 RS RS20251307A patent/RS67563B1/sr unknown
- 2016-01-25 US US15/005,334 patent/US9771414B2/en active Active
- 2016-01-25 MY MYPI2017702504A patent/MY180045A/en unknown
- 2016-01-25 LT LTEPPCT/US2016/014720T patent/LT3250591T/lt unknown
- 2016-01-25 SI SI201631929T patent/SI3250591T1/sl unknown
- 2016-01-25 MY MYPI2021007427A patent/MY196224A/en unknown
- 2016-01-25 PH PH1/2017/501277A patent/PH12017501277B1/en unknown
- 2016-01-25 HR HRP20251642TT patent/HRP20251642T1/hr unknown
- 2016-01-25 MX MX2017009716A patent/MX392533B/es unknown
- 2016-01-25 SM SM20250454T patent/SMT202500454T1/it unknown
- 2016-01-25 EP EP16703030.3A patent/EP3250591B1/en active Active
- 2016-01-25 JP JP2017536549A patent/JP6829199B2/ja active Active
- 2016-01-25 CN CN202110499070.6A patent/CN113354732B/zh active Active
- 2016-01-25 FI FIEP16703030.3T patent/FI3250591T3/fi active
- 2016-01-25 WO PCT/US2016/014720 patent/WO2016123019A1/en not_active Ceased
- 2016-01-25 SG SG10202007835QA patent/SG10202007835QA/en unknown
- 2016-01-25 DK DK16703030.3T patent/DK3250591T3/da active
- 2016-01-25 KR KR1020177021579A patent/KR102641731B1/ko active Active
- 2016-01-25 BR BR112017015845-0A patent/BR112017015845A2/en active IP Right Grant
- 2016-01-25 MY MYPI2019007583A patent/MY189452A/en unknown
- 2016-01-25 SG SG11201705681YA patent/SG11201705681YA/en unknown
- 2016-01-25 MY MYPI2023001378A patent/MY208081A/en unknown
- 2016-01-25 PL PL16703030.3T patent/PL3250591T3/pl unknown
- 2016-01-25 CA CA2974899A patent/CA2974899A1/en active Pending
- 2016-01-25 MD MDE20170310T patent/MD3250591T2/ro unknown
- 2016-01-25 ES ES16703030T patent/ES3054263T3/es active Active
- 2016-01-25 PT PT167030303T patent/PT3250591T/pt unknown
- 2016-01-25 EA EA201791675A patent/EA038993B1/ru unknown
- 2016-01-25 AU AU2016211783A patent/AU2016211783B2/en active Active
- 2016-01-26 UY UY0001036538A patent/UY36538A/es active IP Right Grant
-
2017
- 2017-07-09 IL IL253358A patent/IL253358B/en unknown
- 2017-07-26 MX MX2021015687A patent/MX2021015687A/es unknown
- 2017-07-26 CL CL2017001920A patent/CL2017001920A1/es unknown
- 2017-07-27 CO CONC2017/0007619A patent/CO2017007619A2/es unknown
- 2017-08-28 US US15/688,474 patent/US10081670B2/en active Active
-
2018
- 2018-08-22 US US16/108,096 patent/US10501526B2/en active Active
-
2019
- 2019-10-24 US US16/663,261 patent/US10829544B2/en active Active
-
2020
- 2020-02-28 CL CL2020000498A patent/CL2020000498A1/es unknown
- 2020-05-07 JP JP2020081768A patent/JP7672200B2/ja active Active
- 2020-09-30 US US17/039,557 patent/US11530255B2/en active Active
-
2021
- 2021-05-05 AU AU2021202839A patent/AU2021202839A1/en not_active Abandoned
-
2022
- 2022-11-09 US US18/053,927 patent/US12152067B2/en active Active
- 2022-12-26 CL CL2022003763A patent/CL2022003763A1/es unknown
-
2023
- 2023-03-07 JP JP2023034449A patent/JP2023065648A/ja active Pending
-
2025
- 2025-02-10 JP JP2025019929A patent/JP7796918B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253358A0 (en) | Human antibodies to glycoproteins of Ebola viruses | |
| IL286807A (en) | Antibodies to icos | |
| ZA201803783B (en) | Human immunodeficiency virus neutralizing antibodies | |
| IL246661A0 (en) | Human antibodies to pd–l1 | |
| ZA201707138B (en) | Anti-ceacam6 antibodies and uses thereof | |
| SG11201702606TA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| EP3218397B8 (en) | Neutralizing antibodies to ebola virus glycoprotein and their use | |
| PT3390441T (pt) | Anticorpos neutralizantes do vírus da imunodeficiência humana | |
| GB201522013D0 (en) | Virus | |
| GB201516936D0 (en) | Virus | |
| GB201507419D0 (en) | Virus | |
| GB201507529D0 (en) | Virus preparations | |
| GB201408046D0 (en) | Virus preparations |